Soligenix, Inc. –  In this interview,  Dr. Christopher J. Schaber, President and CEO, discusses the company’s rare disease business, including key Phase 3 clinical programs and biodefense with The Sentinel’s Brett Johnson.

Read Publication Here.

Dr. Christopher J. Schaber’s Interview with OneMed Sentinel
Go Back